• Loading...
    Contact Us

    Birth Defects Epidemiology & Surveillance
    Mail Code 1964
    P.O. Box 149347
    Austin, TX 78714-9347

    Phone: 512-776-7232
    Fax: 512-776-7330

    Email comments or questions

Neural Tube Defects


Birth Defects Risk Factor Series

Click here for an Adobe PDF version of this document. (137KB PDF, Viewing Information)

NEW: Please take a moment to evaluate our birth defects risk factor series. Click here to take survey.

More on NTDs in Texas.


Neural tube defects (NTDs) are a group of birth defects presumed to have a common origin in failure of the neural tube to develop properly during the embryonic stage. NTDs are comprised mainly of anencephaly (including craniorachischisis), spina bifida (including meningomyelocele, meningocele, and myelocele), and encephalocele. Anencephaly involves absence of the skull, with the cerebral hemispheres completely missing or reduced to small masses attached to the base of the skull. Spina bifida (which includes myelomeningocele and meningomyelocele) is defective closure of the bony encasement of the spinal cord, through which the cord and meninges may or may not protrude. Encephalocele is protrusion of some or all of the brain through a defect in the skull.

Approximately 10% or less of NTDs are associated with chromosomal abnormalities (O'Reilly and Shields, 2000). The most common types of chromosomal abnormalities include trisomy 18, trisomy 13, trisomy 21, triploidy, and Turner syndrome.

Over the last several decades, women carrying a fetus with an open NTD have been found to have elevated maternal serum levels of alpha-fetoprotein and reduced levels of human chorionic gonadotropin and unconjugated estriol (Canick and Saller, 1993). Prenatal screening of these substances, along with ultrasonography (Vintzileos et al., 1987), have allowed neural tube defects (NTDs) to be identified in utero. Studies from various birth defects surveillance systems have found that, in regions where elective termination is allowed, prenatal diagnosis and elective termination reduce the birth prevalence of NTDs, with the reduction being greater for anencephaly than for spina bifida (Boyd et al., 2000; Owen et al., 2000; Whiteman et al., 2000; Hendricks et al., 1999; Forrester and Merz, 2000a; Riley et al., 1998; Alembik et al., 1997; Velie and Shaw, 1996; Alembik et al., 1995; CDC, 1995; Roberts et al., 1995; Stoll and EUROCAT Working Group, 1995; Stoll et al., 1995; Julian-Reynier et al., 1994; Bower et al., 1993; Stoll et al., 1992; EUROCAT Working Group, 1991).


Some studies suggest that certain risk factors appear to have greater impact among populations with higher background rates for NTDs than among populations with lower background rates (Little and Elwood, 1991). Also, the etiology of NTDs is very heterogeneic, with the impact of a given risk factor varying by the types of NTD and the presence or absence of other defects (Holmes et al., 1976; Khoury et al., 1982; Sever, 1995). The neural tube closes by approximately the 28th day of gestation (Campbell et al., 1986; Lemire, 1988), so any potential exposures suspected to have caused an NTD would have to have occurred within the first month of gestation.


There are racial/ethnic differences in risk for NTDs. In the United States, NTD prevalence has been reported to be highest among Hispanics, followed in descending order by non-Hispanic whites, Native Americans, African-Americans, and Asians (Owen et al., 2000; Hendricks et al., 1999; Canfield et al., 1996a; Shaw et al., 1994; CDC, 1992; Chavez et al., 1988). One investigation observed no significant difference in risk of anencephaly and spina bifida in infants born to Vietnamese women compared with infants born to non-Hispanic white women in California (Shaw et al., 2002a). Another study reported no significant difference in NTD rates among whites, Far East Asians, Pacific Islanders, and Filipinos (Forrester and Merz, 2000b). Differences in racial/ethnic rates may be due to differences in genetic susceptibility to NTDs, cultural behaviors, diet, or other factors.

Secular trends have been observed in NTD prevalence since the 1970s. Overall, rates for anencephaly and spina bifida have declined in North America, Europe, Australia, and New Zealand (McDonnell et al., 1999; CDC, 1992; Yen et al., 1992; Little and Elwood, 1991; Campbell et al., 1986), although one study reported an increase in NTD rates in the 1980's-1990's (Forrester and Merz, 2000b). The proportion of NTDs that were electively terminated increased with time in some regions studied (Whiteman et al., 2000; CDC, 1995; Bower et al., 1993; EUROCAT Working Group, 1991). Thus, some of this decline in NTD prevalence may be attributable to increased prenatal diagnosis and elective termination of NTD-affected pregnancies. However, this trend was observed prior to the widespread use of prenatal diagnosis and has occurred in areas where elective termination is not allowed.

Prevalence of NTDs shows wide variation by geographic location, both within and between countries. Also, the distribution of the types of NTDs can vary between regions (Forrester and Merz, 2000b). Berry et al., 1999; Hendricks et al., 1999; Moore et al., 1997; Little and Elwood, 1991). NTD rates in the United States and Canada have shown a decrease from east to west (Little and Elwood, 1991; Campbell et al., 1986). Anencephaly prevalence is generally lower in continental Europe than in the British Isles, and shows a decrease from west to east. NTD rates in Australia and New Zealand are similar to those reported for North America and continental Europe (Little and Elwood, 1991). Rates of anencephaly in Asia have been reported to be comparable to those of other regions outside the British Isles, while spina bifida prevalence was lower in Asia than elsewhere (Little and Elwood, 1991). However, NTD prevalence in northern China has been reported to be among the highest in the world (Moore et al., 1997). Some of these reported differences in geographical location prevalence may be due to differences in racial/ethnic compositions of the populations.

One investigation found risk of anencephaly and spina bifida, but not encephalocele, to be higher with lower altitude (Castilla et al., 1999).

Seasonal variations in NTD rates have been reported by some studies but not others (Castilla et al., 1990; Bound et al., 1989).

A number of studies have reported maternal age risk for NTDs to be U-shaped, i.e., highest among youngest and oldest women, while other studies have found risk to decrease with increasing age or the reverse (Owen et al., 2000; Hendricks et al., 1999; McDonnell et al., 1999; Little and Elwood, 1991; Campbell et al., 1986), or clear maternal age trend (Forrester and Merz, 2000b). Paternal age has not been clearly linked to NTD risk (Shaw et al., 1994; Little and Elwood, 1991), although one investigation identified increased NTD risk with lowest and highest paternal age groups (McIntosh et al., 1995).

Parity has shown either a U-shaped pattern of NTD risk, i.e., risk being higher for the lowest and highest number of births (Little and Elwood, 1991; Campbell et al., 1986) or increasing risk with increasing parity (Owen et al., 2000; Whiteman et al., 2000).

NTD risk seems to be greater if a woman has had a previous fetal or infant death, even if the previous infant or fetus did not have an NTD (Owen et al., 2000; Whiteman et al., 2000; Canfield et al., 1996b; Little and Elwood, 1991; Myrianthopoulos and Melnick, 1987). However, it is not clear to what extent recall bias or an undiagnosed NTD in the previous fetal death may contribute to this observation (Little and Elwood, 1991). Moreover, not all investigations have reported this association (Todoroff and Shaw, 2000). Studies examining a potential link between the length of time between pregnancies and NTD risk have also found mixed results (Todoroff and Shaw, 2000). NTD risk does not appear to be related to subfertility (Whiteman et al., 2000).

NTD rates may also be higher among multiple births and with lower birth weight (Owen et al., 2000; Whiteman et al., 2000; Mastroiacovo et al., 1999; Riley et al., 1998; Doyle et al., 1991; Mili et al., 1991; Ramos-Arroyo, 1991) and lower gestational age at delivery (Rasmussen et al., 2001; Shaw et al., 2001a). However, one study reported no relationship between NTD risk and plurality (Kalen, 1986). NTDs have also been associated with intrauterine growth retardation (Khoury et al., 1988). One investigation reported increased risk of encephalocele but not anencephaly or spina bifida with macrosomia (Waller et al., 2001), while another found no association between large for gestational age and anencephaly, spina bifida, or encephalocele (Lapunzina et al., 2002).

Infant sex influences the risk for NTDs. Females are more likely than males to have anencephaly and spina bifida, with the difference greater for the latter defect. This preponderance among females appears to be influenced by the presence of additional birth defects, geographical area, and other factors (Lary and Paulozzi, 2001; Forrester and Merz, 2000b; Whiteman et al., 2000; McDonnell et al., 1999; Hendricks et al., 1999; Berry et al., 1999; Riley et al., 1998; Canfield et al., 1996a; Little and Elwood, 1991). Potential explanations for the preponderance among females include differences between the sexes in embryonic development, susceptibility to teratogenic insult, and spontaneous abortion rates (Little and Elwood, 1991).

The recurrence risk for NTDs is approximately 3-4%, with the risk being slightly higher if the prior infant or fetus had anencephaly (Little and Elwood, 1991). However, 95% of infants with NTDs are born to parents with no family history of the defect. With respect to consanguinity, NTD rates have been found to be higher when the parents are related (Little and Elwood, 1991), although not all studies identified this association (Rittler et al., 2001; Stoltenberg et al., 1997).


Various studies have suggested that NTD risk is higher among families of lower socioeconomic status, although other studies failed to support this (Vrijheid et al., 2000; Wasserman et al., 1998; Little and Elwood, 1991).

Hyperthermia, due to fever or use of saunas and hot tubs, has been linked to increased risk of NTDs, particularly spina bifida, although the results are not consistent (Shaw et al., 1998; Lynberg et al., 1994; Milunsky et al., 1992; Little and Elwood, 1991). Several studies (Shaw et al., 1999a; Dlugosz et al., 1992) found that periconceptional use of electric bed-heating devices (electric blankets, bed warmers, and heated waterbeds) did not appear to affect risk for NTDs.

Women with diabetes are at increased risk for having an infant with a birth defect. The results of several studies suggest that this increased risk applies to NTDs in particular (Janssen et al., 1996; Ramos-Arroyo et al., 1992; Little and Elwood, 1991; Becerra et al., 1990; Myrianthopoulos and Melnick, 1987), although other studies reported no association between maternal diabetes and NTDs (Aberg et al., 2001). Maternal common cold in the first trimester of pregnancy has been reported to increase risk of anencephaly and spina bifida (Zhang and Cai, 1993). Hypothyroidism does not appear to be associated with NTDs, although risk of encephalocele but not spina bifida or anencephaly may be increased with hyperthyroidism (Khoury et al., 1989).

Maternal weight has been associated with NTD risk. Obesity has been linked to increased NTD rates (Kalen, 1998; Shaw et al., 1996; Watkins et al., 1996; Werler et al., 1996; Waller et al., 1994). However, a more recent study failed to find any association between maternal weight and NTD risk (Feldman et al., 1999). The authors of the latter study have suggested that the earlier studies may have suffered from bias in recording of maternal weight or selection of controls. One investigation identified increased risk of NTDs with maternal hyperinsulinemia and suggested that this association may at least partially account for the observed association between maternal obesity and NTD risk (Hendricks et al., 2001). Another study reported higher NTD rates among women who gained less weight during pregnancy (Shaw et al., 2001b). Since weight gain during early pregnancy, the time when NTDs occur, is small and is not consistent, it is not likely that low weight gain is causal for NTDs. More likely, carrying an NTD-affected fetus caused low weight gain throughout the pregnancy, or both conditions are the consequence of a common factor.

Maternal psychosocial or emotional stress during pregnancy may increase risk of having an infant with an NTD (Carmichael and Shaw, 2000).

Epilepsy, and valproic acid and carbamazepine, medications used to treat epilepsy, have been found to increase risk of spina bifida (Arpino et al., 2000; Owen et al., 2000; Lindhout and Omtzigt, 1994; Little and Elwood, 1991). Risk of spina bifida may be related to dosage and to antiepileptic medications used in combination (Lindhout and Omtzigt, 1994). The relationship between maternal smoking and NTD prevalence is unclear (Wasserman et al., 1996; Little and Elwood, 1991; Van Den Eeden et al., 1990; Ericson et al., 1988). One study found not link between paternal smoking and NTD risk (Wasserman et al., 1996).

Increased NTD prevalence has not been associated with maternal infection (Little and Elwood, 1991), alcohol (Little and Elwood, 1991), caffeine (Rosenberg et al., 1982), vitamin A (Mills et al., 1997; Shaw et al., 1997), oral contraceptives (Little and Elwood, 1991), contraceptive spermicides (Louik et al., 1987), ovulation-inducing drugs (Werler et al., 1994), subfertility treatments such as Clomiphene (Whiteman et al., 2000), cough medicines containing dextromethorphan (Martinez-Frias and Rodriguez-Pinilla, 2001), or illicit drugs (Little and Elwood, 1991). A recent study reported increased risk of spina bifida with maternal tea consumption (Correa et al., 2000). NTDs have been associated with maternal use of the antibiotic oxytetracycline but not cephalosporin antibiotics during pregnancy (Czeizel et al., 2001a; Czeizel and Rockenbauer, 2000). Recent studies reported no association between maternal use of nalidixic acid, used to treat bacterial infections, oral antituberculosis medications, or ampicillin and NTDs (Czeizel et al., 2001b; Czeizel et al., 2001c; Czeizel et al., 2001d). A case-control study failed to identify any association between encephalocele risk and misoprostol, a synthetic prostaglandin used for elective termination (Orioli and Castilla, 2000). Another investigation reported no relationship between maternal use of calcium channel blockers and NTDs (Sorensen et al., 2001). Maternal use of the benzodiazepines nitrazepam, medazepam, tofisopam, alprazolum, and clonazepam have not been associated with NTD risk (Eros et al., 2002).

Maternal occupation and maternal exposures have not been clearly or consistently linked to increased NTD risk (Little and Elwood, 1991). However, one study reported increased risk for women working in agricultural occupations or as cleaning women (Blatter et al., 1996). Another investigation identified higher risk of anencephaly and spina bifida with maternal nursing occupation (Matte et al., 1993). One study noted no significant association between NTDs and a variety of paternal occupations (Irgens et al., 2000).

NTD prevalence is increased among women who may have been exposed to glycol ethers (Cordier et al., 1997) and occupational radiation (Sever, 1995; Matte et al., 1993). The literature on the relationship between NTDs and anesthetic gases have reported conflicting results (Sylvester et al., 1994; Matte et al., 1993). Arsenic and lead have also been proposed as potential risk factors for NTDs (Irgens et al., 1998; Bound et al., 1997; Shalat et al., 1996). However, a recent investigation found no association between levels of lead in the water and NTD rates and suggested that previous associations may have been confounded by socioeconomic factors (Macdonell et al., 2000). Another investigation reported higher levels of lead in the amniotic fluid of NTD-affected pregnancies than in pregnancies without NTDs (Dawson et al., 1999). NTDs have not been positively associated with combined chemical exposures (Shaw et al., 2001c).

Paternal exposure to radiation, solvents, pesticides, and mercury, and paternal occupation as a painter have been tentatively linked to increased NTD risk (Sever, 1995), although other investigations reported no association between paternal exposure to pesticides and ionizing radiation and NTDs (Doyle et al., 2000; Shaw et al., 1999b). Several studies have reported increased risk of spina bifida as a result of paternal exposure to the herbicides (including Agent Orange) used in Vietnam (Wolfe et al., 1995; Erickson et al., 1984). Higher rates of spina bifida have also been reported from pesticide use by parental farmers (Kristensen et al., 1997). Increased risk of NTDs has also been reported for pesticides applied to homes (Shaw et al., 1999b).

Living in proximity to hazardous waste sites, landfill sites, and agricultural crops has been reported to increase NTD risk (Elliott et al., 2001; Shaw et al., 1999b; Dolk et al., 1998; Croen et al., 1997; Sever, 1995), as have drinking water contaminants such as disinfection byproducts (Klotz and Pyrch, 1999; Bove et al., 1995; Sever, 1995). However, not all studies reported an association between water disinfection byproducts or chlorination and NTDs (Jaakkola et al., 2001; Kallen and Robert, 2000; Doddes et al., 1999). A recent study found increased risk of anencephaly, but not spina bifida, with exposure to nitrate in drinking water but not in the diet (Croen et al., 2001). Another study reported an association between bromodichloromethane but not chloroform in drinking water and NTDs (Dodds and King, 2001). One investigation reported higher rates of anencephaly with proximity to textile industry, spina bifida with proximity to soap and detergents, iron and steel, machinery, photographic, and rubber industries, and encephalocele with proximity to fur dressing and dyeing industry (Castilla et al., 2000). Another study found increased risk of spina bifida with maternal occupational exposure to electromagnetic fields and increased risk of anencephaly with paternal occupational exposure to electromagnetic fields; however, exposure was based on linkage to census data and exposure assessments by an expert panel (Blaasaas et al., 2002).

Maternal periconceptional use of folic acid has been found to reduce the risk of both recurrent and occurrent NTDs (Locksmith and Diff, 1998; Watkins, 1998; Czeizel et al., 1996). This reduction occurs both in regions of high NTD rates and in regions of low NTD rates (Berry et al., 1999), although several studies have found reduction in risk to be more modest among Hispanics (Suarez et al., 2000; Shaw et al., 1995). This association between NTDs and folic acid is supported by research that has shown that folic acid antagonists, such as aminopterin, methotrexate, valproic acid, carbamazepine, and trimethoprim may increase NTD risk (Czeizel et al., 2001e; Hernandez-Diaz et al., 2001; Campbell et al., 1986). However, a study that examined co-trimoxazole, a combination of trimethoprim and sulfamethoxazole that is a folic acid antagonist, failed to find any association between the medication and NTDs (Czeizel, 1990). Also, thalassemia carriers frequently have low folate levels. One study found a higher NTD risk among thalassemia carriers (Lam and Tang, 1999). It is not known whether folic acid reduces risk of NTDs associated with antiepileptic medications (Lindhout and Omtzigt, 1994).

Exactly how folic acid prevents NTDs is not clear. Folic acid may not reduce NTD risk to the same degree in all racial/ethnic groups (Suarez et al., 2000; Shaw et al., 1995), suggesting that a genetic component may be involved. Recent investigations have suggested that the influence of folic acid use may relate to defects in homocysteine metabolism such as mutations in the methylenetetrahydrofolate reductase (MTHFR) gene (De Marco et al., 2001; Martinez de Villarreal et al., 2001; Volcik et al., 2000; Finnell et al., 1998; Ou et al., 1996; Mills et al., 1995; van der Put et al., 1995; Whitehead; 1995). One study observed an association between reduced folate carrier protein (RFC) gene polymorphism and NTD risk (De Marco et al., 2001), while another study found no such association between the gene and spina bifida (Shaw et al., 2002b). A recent study (Velie and Shaw, 1999) has also suggested that periconceptional intake of zinc can reduce NTD risk, and another study reported methionine use decreases NTD risk (Shoob et al., 2000).

A recent investigation reported no association between mutations in the transcription factor gene ZIC2 and neural tube defects. However, the data did suggest a potential association between a histidine tract polymorphism in the gene and neural tube defects (Brown et al., 2002).


  • Aberg A, Westbom L, Kallen B. Congenital malformations among infants whose mothers had gestational diabetes or preexisting diabetes. Early Hum Dev 2001;61:85-95.
  • Alembik Y, Dott B, Roth MP, Stoll C. Prevalence of neural tube defects in northeastern France, 1979-1994. Impact of prenatal diagnosis. Ann Genet 1997;40:69-71.
  • Alembik Y, Dott B, Roth MP, Stoll C. Prevalence of neural tube defects in northeastern France, 1979-1992 impact of prenatal diagnosis. Ann Genet 1995;38:49-53.
  • Arpino C, Brescianini S, Robert E, Castilla EE, Cocchi G, Cornel MC, de Vigan C, Lancaster PA, Merlob P, Sumiyoshi Y, Zampino G, Renzi C, Rosano A, Mastroiacovo P. Teratogenic effects of antiepileptic drugs: use of an international database on malformations and drug exposure. Epilepsia 2000;41:1436-1443.
  • Becerra JE, Khoury MJ, Cordero JF, Erickson JD. Diabetes mellitus during pregnancy and the risks for specific birth defects: a population-based case-control study. Pediatrics 1990;85:1-9.
  • Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, Mulinare J, Zhao P, Wong LY, Gindler J, Hong SX, Correa A. Prevention of neural-tube defects with folic acid in China. N Engl J Med 1999;341:1485-1490.
  • Blaasaas KG, Tynes T, Irgens A, Lie RT. Risk of birth defects by parental occupational exposure to 50 Hz electromagnetic fields: a population-based study. Occup Environ Med 2002;59:92-97.
  • Blatter BM, Roeleveld N, Zielhuis GA, Gabreels FJ, Verbeek AL. Maternal occupational exposure during pregnancy and the risk of spina bifida. Occup Environ Med 1996;53:80-86.
  • Bound JP, Harvey PW, Francis BJ, Awwad F, Gatrell AC. Involvement of deprivation and environmental lead in neural tube defects: a matched case-control study. Arch Dis Child 1997;76:107-112.
  • Bound JP, Harvey PW, Francis BJ. Seasonal prevalence of major congenital malformations in the Fylde of Lancashire 1957-1981. J Epidemiol Community Health 1989;43:330-342.
  • Bove FJ, Fulcomer MC, Klotz JB, Esmart J, Dufficy EM, Savrin JE. Public drinking water contamination and birth outcomes. Am J Epidemiol 1995;141:850-862.
  • Bower C, Raymond M, Lumley J, Bury G. Trends in neural tube defects 1980-1989. Med J Aust 1993; 158: 152-54.
  • Boyd PA, Wellesley DG, De Walle HE, Tenconi R, Garcia-Minaur S, Zandwijken GR, Stoll C, Clementi M. Evaluation of the prenatal diagnosis of neural tube defects by fetal ultrasonographic examination in different centres across Europe. J Med Screen 2000;7:169-174.
  • Brown LY, Hodge SE, Johnson WG, Guy SG, Nye JS, Brown S. Possible association of NTDs with a polyhistidine tract polymorphism in the ZIC2 gene. Am J Med Genet 2002;108:128-131.
  • Campbell LR, Dayton DH, Sohal GS. Neural tube defects: a review of human and animal studies on the etiology of neural tube defects. Teratology 1986;34:171-187.
  • Canfield MA, Annegers JF, Brender JD, Cooper SP, Greenberg F. Hispanic origin and neural tube defects in Houston/Harris County, Texas. I. Descriptive epidemiology. Am J Epidemiol 1996a;143:1-11.
  • Canfield MA, Annegers JF, Brender JD, Cooper SP, Greenberg F. Hispanic origin and neural tube defects in Houston/Harris County, Texas. II. Risk factors. Am J Epidemiol 1996b;143:12-24.
  • Canick JA, Saller DN. Maternal serum screening for aneuploidy and open fetal defects. Prenat Diagn 1993; 20: 443-54.
  • Carmichael SL, Shaw GM. Maternal life event stress and congenital anomalies. Epidemiology 2000;11:30-35.
  • Castilla EE, Campana H, Camelo JS. Economic activity and congenital anomalies: an ecologic study in Argentina. Environ Health Perspect 2000;108:193-197.
  • Castilla EE, Lopez-Camelo JS, Campana H. Altitude as a risk factor for congenital anomalies. Am J Med Genet 1999;86:9-14.
  • Castilla EE, Orioli IM, Lugarinho R, Dutra GP, Lopez-Camelo JS, Campana HE, Spagnolo A, Mastroiacovo P. Monthly and seasonal variations in the frequency of congenital anomalies. Int J Epidemiol 1990;19:399-404.
  • CDC. Spina bifida incidence at birth - United States, 1983-1990. MMWR Morb Mortal Wkly Rep 1992;41:497-500.
  • CDC. Surveillance for anencephaly and spina bifida and the impact of prenatal diagnosis - United States, 1985-1994. MMWR Morb Mortal Wkly Rep 1995; 44(SS-4): 1-13.
  • Chavez GF, Cordero JF, Becerra JE. Leading major congenital malformations among minority groups in the United States, 1981-1986. Mor Mortal Wkly Rep CDC Surveill Summ 1988;37:17- 24.
  • Cordier S, Bergeret A, Goujard J, Ha MC, Ayme S, Bianchi F, Calzolari E, De Walle HE, Knill- Jones R, Candela S, Dale I, Dananche B, de Vigan C, Fevotte J, Kiel G, Mandereau L. Congenital malformation and maternal occupational exposure to glycol ethers. Occupational Exposure and Congenital Malformations Working Group. Epidemiology 1997;8:355-363.
  • Correa A, Stolley A, Liu Y. Prenatal tea consumption and risks of anencephaly and spina bifida. Ann Epidemiol 2000;10:476-477.
  • Croen LA, Todoroff K, Shaw GM. Maternal exposure to nitrate from drinking water and diet and risk for neural tube defects. Am J Epidemiol 2001;153:325-331.
  • Croen LA, Shaw GM, Sanbonmatsu L, Selvin S, Buffer PA. Maternal residential proximity to hazardous waste sites and risk for selected congenital malformations. Epidemiology 1997;8:347- 354.
  • Czeizel A. A case-control analysis of the teratogenic effects of co-trimoxazole. Reprod Toxicol 1990;4:305-313.
  • Czeizel AE, Toth M, Rockenbauer M. Population-based case control study of folic acid supplementation during pregnancy. Teratology 1996;53:345-351.
  • Czeizel AE, Rockenbauer M. A population-based case-control teratologic study of oral oxytetracycline treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2000;88:27-33.
  • Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: a population-based, case-control study. Am J Obstet Gynecol 2001a;184:1289-1296.
  • Czeizel AE, Sorensen HT, Rockenbauer M, Olsen J. A population-based case-control teratologic study of nalidixic acid. Int J Gynaecol Obstet 2001b;73:221-228.
  • Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT. A population-based case-control study of the safety of oral anti-tuberculosis drug treatment during pregnancy. Int J Tuberc Lung Dis 2001c;5:564-568.
  • Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of ampicillin treatment during pregnancy. Am J Obstet Gynecol 2001d;185:140-147.
  • Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. The teratogenic risk of trimethoprim- sulfonamides: a population based case-control study. Reprod Toxicol 2001e;15:637-646.
  • Dawson EB, Evans DR, Harris WA, Van Hook JW. Amniotic fluid B12, calcium, and lead levels associated with neural tube defects. Am J Perinatol 1999;16:373-378.
  • De Marco P, Calevo MG, Moroni A, Arata L, Merello E, Cama A, Finnell RH, Andreussi L, Capra V. Polymorphisms in Genes Involved in Folate Metabolism as Risk Factors for NTDs. Eur J Pediatr Surg 2001;11:S14-S17.
  • Dlugosz L, Vena J, Byers T, Sever L, Bracken M, Marshall E. Congenital defects and electric bed heating in New York State: a register-based case-control study. Am J Epidemiol 1992;135:1000- 1011.
  • Dodds L, King W, Woolcott C, Pole J. Trihalomethanes in public water supplies and adverse birth outcomes. Epidemiology 1999;10:233-237.
  • Dodds L, King WD. Relation between trihalomethane compounds and birth defects. Occup Environ Med 2001;58:443-446.
  • Dolk H, Vrijheid M, Armstrong B, Abramsky L, Bianchi F, Garne E, Nelen V, Robert E, Scott JE, Stone D, Tenconi R. Risk of congenital anomalies near hazardous-waste landfill sites in Europe: the EUROHAZCON study. Lancet 1998;352:423-427.
  • Doyle PE, Beral V, Botting B, Wale CJ. Congenital malformations in twins in England and Wales. J Epidemiol Community Health 1991;45:43-48.
  • Doyle P, Maconochie N, Roman E, Davies G, Smith PG, Beral V. Fetal death and congenital malformation in babies born to nuclear industry employees: report from the nuclear industry family study. Lancet 2000;356:1293-1299.
  • Elliott P, Briggs D, Morris S, de Hoogh C, Hurt C, Jensen TK, Maitland I, Richardson S, Wakefield J, Jarup L. Risk of adverse birth outcomes in populations living near landfill sites. BMJ 2001;323:363-368.
  • Erickson JD, Mulinare J, McClain PW, Fitch TG, James LM, McClearn AB, Adams MJ. Vietnam veterans' risks for fathering babies with birth defects. JAMA 1984;252:903-912.
  • Ericson A, Kallen B, Lofkvist E. Environmental factors in the etiology of neural tube defects: a negative study. Environ Re 1988;45:38-47.
  • Eros E, Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2002;101:147-154.
  • EUROCAT Working Group. Prevalence of neural tube defects in 20 regions of Europe and the impact of prenatal diagnosis, 1980-1986. J Epidemiol Community Health 1991; 45: 52-58.
  • Feldman B, Yaron Y, Critchfield G, Leon J, O'Brien JE, Johnson MP, Evans MI. Distribution of neural tube defects as a function of maternal weight: No apparent correlation. Fetal Diagn Ther 1999;14:185-189.
  • Finnell RH, Greer KA, Barber RC, Piedrahita JA. Neural tube and craniofacial defects with special emphasis on folate pathway genes. Crit Rev Oral Biol Med 1998;9:38-53.
  • Forrester MB, Merz RD. Prenatal Diagnosis and Elective Termination of Neural Tube Defects in Hawaii, 1986-1997. Fetal Diagn Ther 2000a;15:146-151.
  • Forrester MB, Merz RD. Epidemiology of neural tube defects, Hawaii, 1986-1997. Hawaii Med J 2000b;323-327,341.
  • Hendricks KA, Simpson JS, Larsen RD. Neural tube defects along the Texas-Mexico border, 1993-1995. Am J Epidemiol 1999;149:1119-1127.
  • Hendricks KA, Nuno OM, Suarez L, Larsen R. Effects of hyperinsulinemia and obesity on risk of neural tube defect among Mexican Americans. Epidemiology 2001;12:630-635.
  • Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001;153:961-968.
  • Holmes LB, Driscoll SG, Atkins L. Etiologic heterogeneity of neural-tube defects. N Engl J Med 1976;294:365-369.
  • Irgens A, Kruger K, Skorve AH, Irgens LM. Birth defects and paternal occupational exposure. Hypotheses tested in a record linkage based dataset. Acta Obstet Gynecol Scand 2000;79:465- 470.
  • Irgens A, Kruger K, Skorve AH, Irgens LM. Reproductive outcome in offspring of parents occupationally exposed to lead in Norway. Am J Ind Med 1998;34:431-437.
  • Jaakkola JJ, Magnus P, Skrondal A, Hwang BF, Becher G, Dybing E. Foetal growth and duration of gestation relative to water chlorination. Occup Environ Med 2001 Jul;58(7):437-442.
  • Janssen PA, Rothman I, Schwartz SM. Congenital malformations in newborns of women with established and gestational diabetes in Washington State, 1984-1991. Paediatr Perinat Epidemiol 1996;10:52-63.
  • Julian-Reynier C, Philip N, Scheiner C, Aurran Y, Chabal F, Maron A, Gombert A, Ayme S. Impact of prenatal diagnosis by ultrasound on the prevalence of congenital anomalies at birth in southern France. J Epidemiol Community Health 1994;48:290-296.
  • Kallen K. Maternal smoking, body mass index, and neural tube defects. Am J Epidemiol 1998;147:1103-1111.
  • Kallen B. Congenital malformations in twins: a population study. Acta Genet Med Gemellol (Roma) 1986;35:167-178.
  • Kallen BA, Robert E. Drinking water chlorination and delivery outcome-a registry-based study in Sweden. Reprod Toxicol 2000;14:303-309.
  • Khoury MJ, Becerra JE, d'Almada PJ. Maternal thyroid disease and risk of birth defects in offspring: a population-based case-control study. Paediatr Perinat Epidemiol 1989;3:402-420.
  • Khoury MJ, Erickson JD, Cordero JF, McCarthy BJ. Congenital malformations and intrauterine growth retardation: a population study. Pediatrics 1988;82:83-90.
  • Khoury MJ, Erickson JD, James LM. Etiologic heterogeneity of neural tube defects: Clues from epidemiology. Am J Epidemiol 1982;115:538-548.
  • Klotz JB, Pyrch LA. Neural tube defects and drinking water disinfection by-products. Epidemiology 1999;10:383-390.
  • Kristensen P, Irgens LM, Andersen A, Bye AS, Sundheim L. Birth defects among offspring of Norwegian farmers, 1967-1991.Epidemiology 1997;8:537-544.
  • Lam YH, Tang MH. Risk of neural tube defects in the offspring of thalassaemia carriers in Hong Kong Chinese. Prenat Diagn 1999;19:1135-1137.
  • Lapunzina P, Lopez Camelo JS, Rittler M, Castilla EE. Risks of congenital anomalies in large for gestational age infants. J Pediatr 2002;140:200-204.
  • Lary JM, Paulozzi LJ. Sex differences in the prevalence of human birth defects: a population- based study. Teratology 2001;64:237-251.
  • Lemire RJ. Neural tube defects. JAMA 1988;259:558-562.
  • Lindhout D, Omtzigt JG. Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia 1994;35 Suppl 4:S19-28.
  • Little L, Elwood JM. Epidemiology of neural tube defects. Reproductive and Perinatal Epidemiology. Kiley M, Ed., CRC Press, Boston, 1991, 251-336.
  • Locksmith GJ, Diff P. Preventing neural tube defects: The importance of periconceptional folic acid supplements. Obstet Gynecol 1998;91:1027-1034.
  • Louik C, Mitchell AA, Werler MM, Hanson JW, Shapiro S. Maternal exposure to spermicides in relation to certain birth defects. N Engl J Med 1987;317:474-478.
  • Lynberg MC, Khoury MJ, Lu X, Cocian T. Maternal flu, fever, and the risk of neural tube defects: a population-based case-control study. Am J Epidemiol 1994;140:244-255.
  • Macdonell JE, Campbell H, Stone DH. Lead levels in domestic water supplies and neural tube defects in Glasgow. Arch Dis Child 2000;82:50-53.
  • Martinez de Villarreal LE, Delgado-Enciso I, Valdez-Leal R, Ortiz-Lopez R, Rojas-Martinez A, Limon-Benavides C, Sanchez-Pena MA, Ancer-Rodriguez J, Barrera-Saldana HA, Villarreal- Perez JZ. Folate levels and N(5),N(10)-methylenetetrahydrofolate reductase genotype (MTHFR) in mothers of offspring with neural tube defects: a case-control study. Arch Med Res 2001;32:277-282
  • Martinez-Frias ML, Rodriguez-Pinilla E. Epidemiologic analysis of prenatal exposure to cough medicines containing dextromethorphan: No evidence of human teratogenicity. Teratology 2001;63:38-41.
  • Mastroiacovo P, Castilla EE, Arpino C, Botting B, Cocchi G, Goujard J, Marinacci C, Merlob P, Metneki J, Mutchinick O, Ritvanen A, Rosano A. Congenital malformations in twins: an international study. Am J Med Genet 1999;83:117-124.
  • Matte TD, Mulinare J, Erickson JD. Case-control study of congenital defects and parental employment in health care. Am J Ind Med 1993;24:11-23.
  • McDonnell RJ, Johnson Z, Delaney V, Dack P. East Ireland 1980-1994: Epidemiology of neural tube defects. J Epidemiol Community Health 1999;53:782-788.
  • McIntosh GC, Olshan AF, Baird PA. Paternal age and the risk of birth defects in offspring. Epidemiology 1995;6:282-288.
  • Mili F, Edmonds LD, Khoury MJ, McClearn AB. Prevalence of birth defects among low-birth- weight infants. A population study. Am J Dis Child 1991;145:1313-1318.
  • Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, Scott JM. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995;345:149-151.
  • Mills JL, Simpson JL, Cunningham GC, Conley MR, Rhoads GG. Vitamin A and birth defects. Am J Obstet Gynecol 1997;177:31-36.
  • Milunsky A, Ulcickas M, Rothman KJ, Willett W, Jick SS, Jick H. Maternal heat exposure and neural tube defects. JAMA 1992;268:882-885.
  • Moore CA, Li S, Li Z, Hong SX, Gu HQ, Berry RJ, Mulinare J, Erickson JD. Elevated rates of severe neural tube defects in a high-prevalence area in northern China. Am J Med Genet 1997;73:113-118.
  • Myrianthopoulos NC, Melnick M. Studies in neural tube defects I. Epidemiologic and etiologic aspects. Am J Med Genet 1987;26:783-796.
  • O'Reilly GC, Shields LE. Karyotyping for isolated neural tube defects. A report of two cases. J Reprod Med 2000;45:950-952.
  • Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG 2000;107:519-523.
  • Ou CY, Stevenson RE, Brown VK, Schwartz CE, Allen WP, Khoury MJ, Rozen R, Oakley GP Jr, Adams MJ. 5,10 Methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet 1996;63:610-614.
  • Owen TJ, Halliday JL, Stone CA. Neural tube defects in Victoria, Australia: potential contributing factors and public health implications. Aust N Z J Public Health 2000;24:584-589.
  • Ramos-Arroyo MA. Birth defects in twins: study in a Spanish population. Acta Genet Med Gemellol (Roma) 1991;40:337-344.
  • Ramos-Arroyo MA, Rodriguez-Pinilla E, Cordero JF. Maternal diabetes: the risk for specific birth defects. Eur J Epidemiol 1992;8:503-508.
  • Rasmussen SA, Moore CA, Paulozzi LJ, Rhodenhiser EP. Risk for birth defects among premature infants: A population-based study. J Pediatr 2001;138:668-673.
  • Riley MM, Halliday JL, Lumley JM. Congenital malformations in Victoria, Australia, 1983-95: an overview of infant characteristics. J Paediatr Child Health 1998;34:233-240.
  • Rittler M, Liascovich R, Lopez-Camelo J, Castilla EE. Parental consanguinity in specific types of congenital anomalies. Am J Med Genet 2001;102:36-43.
  • Roberts HE, Moore CA, Cragan JD, Fernhoff PM, Khoury MJ. Impact of prenatal diagnosis on the birth prevalence of neural tube defects, Atlanta, 1990-1991. Pediatrics 1995; 96: 880-83.
  • Rosenberg L, Mitchell AA, Shapiro Samuel, Sloane D. Selected birth defects in relation to caffein-containing beverages. JAMA 1982;247:1429-1432.
  • Sever LE. Looking for causes of neural tube defects: where does the environment fit in? Environ Health Perspect 1995;103 Suppl 6:165-171.
  • Shalat SL, Walker DB, Finnell RH. Role of arsenic as a reproductive toxin with particular attention to neural tube defects. J Toxicol Environ Healt 1996;48:253-272.
  • Shaw GM, Carmichael SL, Nelson V. Congenital malformations in offspring of Vietnamese women in California, 1985-97. Teratology 2002a;65:121-124.
  • Shaw GM, Lammer EJ, Zhu H, Baker MW, Neri E, Finnell RH. Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am J Med Genet 2002b;108:1-6.
  • Shaw GM, Savitz DA, Nelson V, Thorp JM. Role of structural birth defects in preterm delivery. Paediatri Perinat Epidemiol 2001a;15:106-109.
  • Shaw GM, Todoroff K, Carmichael SL, Schaffer DM, Selvin S. Lowered weight gain during pregnancy and risk of neural tube defects among offspring. Int J Epidemiol 2001b;30:60-65.
  • Shaw GM, Selvin S, Carmichael SL, Schaffer DM, Nelson V, Neri E. Assessing combined chemical exposures as risk factors for neural tube defects. Reprod Toxicol 2001c;15:631-635.
  • Shaw GM, Nelson V, Todoroff K, Wasserman CR, Neutra RR. Maternal periconceptional use of electric bed-heating devices and risk for neural tube defects and orofacial clefts. Teratology 1999a;60:124-129.
  • Shaw GM, Wasserman CR, O'Malley CD, Nelson V, Jackson RJ. Maternal pesticide exposure from multiple sources and selected congenital anomalies. Epidemiology 1999b;10:60-66.
  • Shaw GM, Todoroff K, Velie EM, Lammer EJ. Maternal illness, including fever and medication use as risk factors for neural tube defects. Teratology 1998;57:1-7.
  • Shaw GM, Velie EM, Schaffer D, Lammer EJ. Periconceptional intake of vitamin A among women and risk of neural tube defect-affected pregnancies. Teratology 1997;55:132-133.
  • Shaw GM, Velie EM, Schaffer D. Risk of neural tube defect-affected pregnancies among obese women. JAMA 1996;275:1093-1096.
  • Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology 1995;6:219-226.
  • Shaw GM, Jensvold NG, Wasserman CR, Lammer EJ. Epidemiologic characteristics of phenotypically distinct neural tube defects among 0.7 million California births, 1983-87. Teratology 1994;49:143-149.
  • Shoob HD, Thompson SJ, Sargent RG, Best RG, Drane JW, Tocharoen A. Methionine in the multifactorial etiology of neural tube defect affected pregnancies. Ann Epidemiol 2000;10:476.
  • Sorensen HT, Czeizel AE, Rockenbauer M, Steffensen FH, Olsen J. The risk of limb deficiencies and other congenital abnormalities in children exposed in utero to calcium channel blockers. Acta Obstet Gynecol Scand 2001;80:397-401.
  • Stoll C, EUROCAT Working Group. Distribution of single organ malformations in European populations. Ann Genet 1995;38:32-43.
  • Stoll C, Dott B, Alembik Y, Roth MP. Evaluation of routine prenatal diagnosis by a registry of congenital anomalies. Prenat Diagn 1995;15:791-800.
  • Stoll C, Alembik Y, Dott B, Roth MP, Finck S. Evaluation of prenatal diagnosis by a registry of congenital anomalies. Prenat Diagn 1992;12:263-270.
  • Stoltenberg C, Magnus P, Lie RT, Daltveit AK, Irgens LM. Birth defects and parental consanguinity in Norway. Am J Epidemiol 1997;145:439-448.
  • Suarez L, Hendricks KA, Cooper SP, Sweeney AM, Hardy RJ, Larsen RD. Neural tube defects among Mexican Americans living on the US-Mexico border: effects of folic acid and dietary folate. Am J Epidemiol 2000;152:1017-1023.
  • Sylvester GC, Khoury MJ, Lu X, Erickson JD. First-trimester anesthesia exposure and the risk of central nervous system defects: a population-based case-control study. Am J Public Health 1994;84:1757-1760.
  • Todoroff K, Shaw GM. Prior spontaneous abortion, prior elective termination, interpregnancy interval, and risk of neural tube defects. Am J Epidemiol 2000;151:505-11.
  • Van Den Eeden, SK, Karagas MR, Daling JR, Vaughan TL. A case-control study of maternal smoking and congenital malformations. Paediatr Perinat Epidemiol 1990;4:147-155.
  • van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, Mariman EC, den Heyer M, Rozen R, Blom HJ. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995;346:1070-1071.
  • Velie EM, Shaw GM. Impact of prenatal diagnosis and elective termination on prevalence and risk estimates of neural tube defects in California, 1989-1991. Am J Epidemiol 1996; 144: 473- 79.
  • Velie EM, Block G, Shaw GM, Samuels SJ, Schaffer DM, Kulldorff M. Maternal supplemental and dietary zinc intake and the occurrence of neural tube defects in California. Am J Epidemiol 1999;150:605-616.
  • Vintzileos AM, Campbell WA, Nochimson DJ, Weinbaum PJ. Antenatal evaluation and management of ultrasonically detected fetal anomalies. Obstet Gynecol 1987; 69: 640-60.
  • Volcik KA, Blanton SH, Tyerman GH, Jong ST, Rott EJ, Page TZ, Romaine NK, Northrup H. Methylenetetrahydrofolate reductase and spina bifida: evaluation of level of defect and maternal genotypic risk in Hispanics. Am J Med Genet 2000;95:21-27.
  • Vrijheid M, Dolk H, Stone D, Abramsky L, Alberman E, Scott JE. Socioeconomic inequalities in risk of congenital anomaly. Arch Dis Child 2000;82:349-52.
  • Waller DK, Mills JL, Simpson JL, Cunningham GC, Conley MR, Lassman MR, Rhoads GG. Are obese women at higher risk for producing malformed offspring? Am J Obstet Gynecol 1994;170:541-548.
  • Waller DK, Keddie AM, Canfield MA, Scheuerle AE. Do infants with major congenital anomalies have an excess of macrosomia? Teratology 2001;64:311-317.
  • Wasserman CR, Shaw GM, Selvin S, Gould JB, Syme SL. Socioeconomic status, neighborhood social conditions, and neural tube defects. Am J Public Health 1998;88:1674-1680.
  • Wasserman CR, Shaw GM, O'Malley CD, Tolarova MM, Lammer EJ. Parental cigarette smoking and risk for congenital anomalies of the heart, neural tube, or limb. Teratology 1996;53:261-267.
  • Watkins ML. Efficacy of folic acid prophylaxis for the prevention of neural tube defects. Mental Retardation and Development Disabilities 1998;4:282-290.
  • Watkins ML, Scanlon KS, Mulinare J, Khoury MJ. Is maternal obesity a risk factor for anencephaly and spina bifida? Epidemiology 1996;7:507-512.
  • Werler MM, Louik C, Shapiro S, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects. JAMA 1996;275:1089-1092.
  • Werler MM, Louik C, Shapiro S, Mitchell AA. Ovulation induction and risk of neural tube defects. Lancet 1994;344:445-446.
  • Whitehead AS, Gallagher P, Mills JL, Kirke PN, Burke H, Molloy AM, Weir DG, Shields DC, Scott JM. A genetic defect in 5,10 methylene tetrahydrofolate reductase in neural tube defects. QJM 1995;88:763-766
  • Whiteman D, Murphy M, Hey K, O'Donnell M, Goldacre M. Reproductive factors, subfertility, and risk of neural tube defects: a case-control study based on the Oxford Record Linkage Study Register. Am J Epidemiol 2000;152:823-828.
  • Wolfe WH, Michalek JE, Miner JC, Rahe AJ, Moore CA, Needham LL, Patterson DG. Paternal serum dioxin and reproductive outcomes among veterans of Operation Ranch Hand. Epidemiology 1995;6:17-22.
  • Yen IH, Khoury MJ, Erickson JD, James LM, Waters GD, Berry RJ. The changing epidemiology of neural tube defect, United States, 1968-1989. Am J Dis Child. 1992;146:857-861.
  • Zhang J, Cai WW. Association of the common cold in the first trimester of pregnancy with birth defects. Pediatrics 1993;92:559-563.

Please Note: The primary purpose of this report is to provide background necessary for conducting cluster investigations. It summarizes literature about risk factors associated with this defect. The strengths and limitations of each reference were not critically examined prior to inclusion in this report. Consumers and professionals using this information are advised to consult the references given for more in-depth information. 

This report is for information purposes only and is not intended to diagnose, cure, mitigate, treat, or prevent disease or other conditions and is not intended to provide a determination or assessment of the state of health. Individuals affected by this condition should consult their physician and when appropriate, seek genetic counseling.

For more information:

Birth Defects Epidemiology and Surveillance

Texas Department of State Health Services
1100 W. 49th Street, Austin, Texas 78756
512-776-7232 Fax 512-776-7330

Return to Birth Defects Risk Factor Page

Document E58-10957H                    Revised May 2006.

Birth Defects Epidemiology and Surveillance Home Page

Last updated September 23, 2013